RESUMO
Covalent drugs have been intensively studied in some very important fields such as anti-tumor and anti-virus, including the currently global-spread SARS-CoV-2. However, these drugs may interact with a variety of biological macromolecules and cause serious toxicology, so how to reactivate the inhibited targets seems to be imperative in the near future. Organophosphate was an extreme example, which could form a covalent bound easily with acetylcholinesterase and irreversibly inhibited the enzyme, causing high toxicology. Some nucleophilic oxime reactivators for organophosphate poisoned acetylcholinesterase had been developed, but the reactivation process was still less understanding. Herein, we proposed there should be a pre-reactivated pose during the reactivating process and compounds whose binding pose was easy to transfer to the pre-reactivated pose might be efficient reactivators. Then we refined the previous reactivators based on the molecular dynamic simulation results, the resulting compounds L7R3 and L7R5 were proven as much more efficient reactivators for organophosphate inhibited acetylcholinesterase than currently used oximes. This work might provide some insights for constructing reactivators of covalently inhibited targets by using computational methods.
Assuntos
Acetilcolinesterase/química , Reativadores da Colinesterase/química , Acetilcolinesterase/metabolismo , Inibidores da Colinesterase/química , Reativadores da Colinesterase/metabolismo , Humanos , Cinética , Simulação de Dinâmica Molecular , Compostos Organofosforados/química , Estudo de Prova de Conceito , Ligação ProteicaRESUMO
We detail here distinctive departures from lead classical cholinesterase re-activators, the pyridinium aldoximes, to achieve rapid CNS penetration and reactivation of AChE in the CNS (brain and spinal cord). Such reactivation is consistent with these non-canonical re-activators enhancing survival parameters in both mice and macaques following exposure to organophosphates. Thus, the ideal cholinesterase re-activator should show minimal toxicity, limited inhibitory activity in the absence of an organophosphate, and rapid CNS penetration, in addition to its nucleophilic potential at the target, the conjugated AChE active center. These are structural properties directed to reactivity profiles at the conjugated AChE active center, reinforced by the pharmacokinetic and tissue disposition properties of the re-activator leads. In the case of nicotinic acetylcholine receptor (nAChR) agonists and antagonists, with the many existing receptor subtypes in mammals, we prioritize subtype selectivity in their design. In contrast to nicotine and its analogues that react with panoply of AChR subtypes, the substituted di-2-picolyl amine pyrimidines possess distinctive ionization characteristics reflecting in selectivity for the orthosteric site at the α7 subtypes of receptor. Here, entry to the CNS should be prioritized for the therapeutic objectives of the nicotinic agent influencing aberrant CNS activity in development or in the sequence of CNS ageing (longevity) in mammals, along with general peripheral activities controlling inflammation.
Assuntos
Acetilcolinesterase/química , Reativadores da Colinesterase/química , Desenho de Fármacos , Agonistas Nicotínicos/química , Antagonistas Nicotínicos/química , Receptores Nicotínicos/química , Acetilcolinesterase/metabolismo , Animais , Reativadores da Colinesterase/metabolismo , Humanos , Ligantes , Agonistas Nicotínicos/metabolismo , Antagonistas Nicotínicos/metabolismo , Estrutura Secundária de Proteína , Estrutura Terciária de Proteína , Receptores Nicotínicos/metabolismoRESUMO
The ability to overcome cellular barriers in the body is crucial for efficient delivery of drugs to the target where intervention is needed. For drugs acting in the brain it is essential to overcome the blood-brain barrier (BBB). Such drugs include antidotes for the treatment of organophosphate poisoning, a current warfare and terroristic threat. Being lipophilic compounds, organophosphates readily penetrate the brain and block the enzyme acetylcholinesterase (AChE). They cause severe symptoms which may have fatal consequences. A major drawback of currently available oxime reactivators is their inability to reactivate AChE in the central nervous system (CNS) as they are unable to cross the blood-brain barrier. An important obstacle preventing many drugs from reaching their therapeutic target in the brain is the efflux transporter P-glycoprotein (P-gp), whose function is to prevent the penetration of potentially harmful substances. The aim of this study was to evaluate the effect of P-gp on the permeation of oximes into the brain. The study of this interaction was carried out on the CACO-2 cell line, stably expressing P-gp. As it turned out, P-gp has no essential influence on the central availability of clinically used oxime reactivators within this study.
Assuntos
Membro 1 da Subfamília B de Cassetes de Ligação de ATP/metabolismo , Antídotos/metabolismo , Encéfalo/metabolismo , Reativadores da Colinesterase/metabolismo , Oximas/metabolismo , Transporte Biológico , Células CACO-2 , HumanosRESUMO
Since several decades oximes have been used as part of treatment of nerve agent intoxication with the aim to restore the biological function of the enzyme acetylcholinesterase after its covalent inhibition by organophosphorus compounds such as pesticides and nerve agents. Recent findings have illustrated that, besides oximes, certain Mannich phenols can reactivate the inhibited enzyme very effectively, and may therefore represent an attractive complementary class of reactivators. In this paper we further probe the effect of structural variation on the in vitro efficacy of Mannich phenol based reactivators. Thus, we present the synthesis of 14 compounds that are close variants of the previously reported 4-amino-2-(1-pyrrolidinylmethyl)-phenol, a very effective non-oxime reactivator, and 3 dimeric Mannich phenols. All compounds were assessed for their ability to reactivate human acetylcholinesterase inhibited by the nerve agents VX, tabun, sarin, cyclosarin and paraoxon in vitro. It was confirmed that the potency of the compounds is highly sensitive to small structural changes, leading to diminished reactivation potency in many cases. However, the presence of 4-substituted alkylamine substituents (as exemplified with the 4-benzylamine-variant) was tolerated. More surprisingly, the dimeric compounds demonstrated non-typical behavior and displayed some reactivation potency as well. Both findings may open up new avenues for designing more effective non-oxime reactivators.
Assuntos
Acetilcolinesterase/metabolismo , Inibidores da Colinesterase/química , Inibidores da Colinesterase/farmacologia , Agentes Neurotóxicos/química , Agentes Neurotóxicos/farmacologia , Oximas/química , Oximas/farmacologia , Substâncias para a Guerra Química/química , Substâncias para a Guerra Química/farmacologia , Reativadores da Colinesterase/metabolismo , Eritrócitos/efeitos dos fármacos , Eritrócitos/metabolismo , Humanos , Relação Estrutura-AtividadeRESUMO
Studies with oximes have been extensively developed to design new reactivators with better efficiency, and greater spectrum of action. In this study, we aimed to analyze the influence of the Carbamoyl group position change in two isomeric oximes, K203 and K206, on the reactivation percentage of Mus musculus Acetylcholinesterase (MmAChE), inhibited by different nerve agents. Theoretical calculations were performed to assess the difference for the oxime activity with inhibited AChE-complexes and the factors that govern this difference. Comparing theoretical and experimental data, it is possible to observe that this change between the oximes results in different reactivation percentage for the same nerve agent, due to the different interaction modes and activation energy for the studied systems.
Assuntos
Acetilcolinesterase/metabolismo , Reativadores da Colinesterase/química , Compostos Organofosforados/química , Oximas/química , Acetilcolinesterase/química , Animais , Sítios de Ligação , Reativadores da Colinesterase/metabolismo , Desenho de Fármacos , Camundongos , Simulação de Acoplamento Molecular , Agentes Neurotóxicos/química , Agentes Neurotóxicos/metabolismo , Compostos Organofosforados/metabolismo , Compostos Organotiofosforados/química , Compostos Organotiofosforados/metabolismo , Teoria Quântica , TermodinâmicaRESUMO
Poisoning by organophosphates (OPs) takes one of the leading places in the total number of exotoxicoses. Detoxication of OPs at the first stage of the poison entering the body could be achieved with the help of DNA- or RNA-aptamers, which are able to bind poisons in the bloodstream. The aim of the research was to develop an approach to rational in silico design of aptamers for OPs based on the example of paraoxon. From the published sequence of an aptamer binding organophosphorus pesticides, its three-dimensional model has been constructed. The most probable binding site for paraoxon was determined by molecular docking and molecular dynamics (MD) methods. Then the nucleotides of the binding site were mutated consequently and the values of free binding energy have been calculated using MD trajectories and MM-PBSA approach. On the basis of the energy values, two sequences that bind paraoxon most efficiently have been selected. The value of free binding energy of paraoxon with peripheral anionic site of acetylcholinesterase (AChE) has been calculated as well. It has been revealed that the aptamers found bind paraoxon more effectively than AChE. The peculiarities of paraoxon interaction with the aptamers nucleotides have been analyzed. The possibility of improving in silico approach for aptamer selection is discussed.
Assuntos
Aptâmeros de Nucleotídeos/metabolismo , Reativadores da Colinesterase/metabolismo , Paraoxon/metabolismo , Acetilcolinesterase/química , Acetilcolinesterase/metabolismo , Aptâmeros de Nucleotídeos/química , Aptâmeros de Nucleotídeos/genética , Sítios de Ligação , Reativadores da Colinesterase/química , Desenho de Fármacos , Humanos , Ligação de Hidrogênio , Simulação de Acoplamento Molecular , Simulação de Dinâmica Molecular , Mutação , Paraoxon/química , Ligação Proteica , Eletricidade EstáticaRESUMO
K-oximes were developed as modern drug candidates acting as AChE reactivators. In this study, it has been investigated which interspecies and intergender differences changes could be observed in Wistar rats and Swiss mice, both genders, after the treatment with increasing doses of selected acetylcholinesterase reactivators - asoxime, obidoxime, K027, K048, and K075. After the 24â¯h, a number of died animals was counted and the median lethal dose (LD50) for each oxime was calculated. By using the intramuscular route of administration, asoxime and K027 had the least toxicity in female rats (640.21â¯mg/kg and 686.08â¯mg/kg), and in female mice (565.75â¯mg/kg and 565.74â¯mg/kg), respectively. Moreover, asoxime and K027 showed 3, 4 or 8 times less acute toxicity in comparison to K048, obidoxime and K075, respectively. Beyond, K075 had the greatest toxicity in male rats (81.53â¯mg/kg), and in male mice (57.34â¯mg/kg), respectively. Our results can help to predict likely adverse toxic effects, target organ systems and possible outcome in the event of massive human overexposure, and in establishing risk categories or in dose selection for the initial repeated dose toxicity tests to be conducted for each oxime.
Assuntos
Oximas/toxicidade , Testes de Toxicidade Aguda/métodos , Acetilcolinesterase/química , Acetilcolinesterase/metabolismo , Animais , Reativadores da Colinesterase/química , Reativadores da Colinesterase/metabolismo , Reativadores da Colinesterase/toxicidade , Feminino , Dose Letal Mediana , Masculino , Camundongos , Cloreto de Obidoxima/toxicidade , Pró-Fármacos/toxicidade , Ratos , Ratos WistarRESUMO
Casualties caused by nerve agents, potent acetylcholinesterase inhibitors, have attracted attention from media recently. Poisoning with these chemicals may be fatal if not correctly addressed. Therefore, research on novel antidotes is clearly warranted. Pyridinium oximes are the only clinically available compounds, but poor penetration into the blood-brain barrier hampers efficient enzyme reactivation at the central nervous system. In searching for structural factors that may be explored in SAR studies, we synthesized and evaluated neutral aryloximes as reactivators for acetylcholinesterase inhibited by NEMP, a VX surrogate. Although few tested compounds reached comparable reactivation results with clinical standards, they may be considered as leads for further optimization.
Assuntos
Acetilcolinesterase/metabolismo , Reativadores da Colinesterase/síntese química , Oximas/química , Pirrolidinas/química , Acetilcolinesterase/química , Animais , Antídotos/síntese química , Antídotos/metabolismo , Inibidores da Colinesterase/química , Inibidores da Colinesterase/metabolismo , Reativadores da Colinesterase/metabolismo , Enguias , Compostos Organotiofosforados/química , Compostos Organotiofosforados/metabolismo , Oximas/metabolismo , Pirrolidinas/metabolismo , Relação Estrutura-AtividadeRESUMO
Organophosphorus (OP) nerve agents and pesticides present significant threats to civilian and military populations. OP compounds include the nefarious G and V chemical nerve agents, but more commonly, civilians are exposed to less toxic OP pesticides, resulting in the same negative toxicological effects and thousands of deaths on an annual basis. After decades of research, no new therapeutics have been realized since the mid-1900s. Upon phosphylation of the catalytic serine residue, a process known as inhibition, there is an accumulation of acetylcholine (ACh) in the brain synapses and neuromuscular junctions, leading to a cholinergic crisis and eventually death. Oxime nucleophiles can reactivate select OP-inhibited acetylcholinesterase (AChE). Yet, the fields of reactivation of AChE and butyrylcholinesterase encounter additional challenges as broad-spectrum reactivation of either enzyme is difficult. Additional problems include the ability to cross the blood brain barrier (BBB) and to provide therapy in the central nervous system. Yet another complication arises in a competitive reaction, known as aging, whereby OP-inhibited AChE is converted to an inactive form, which until very recently, had been impossible to reverse to an active, functional form. Evaluations of uncharged oximes and other neutral nucleophiles have been made. Non-oxime reactivators, such as aromatic general bases and Mannich bases, have been developed. The issue of aging, which generates an anionic phosphylated serine residue, has been historically recalcitrant to recovery by any therapeutic approach-that is, until earlier this year. Mannich bases not only serve as reactivators of OP-inhibited AChE, but this class of compounds can also recover activity from the aged form of AChE, a process referred to as resurrection. This review covers the modern efforts to address all of these issues and notes the complexities of therapeutic development along these different lines of research.
Assuntos
Acetilcolinesterase/metabolismo , Butirilcolinesterase/metabolismo , Inibidores da Colinesterase/metabolismo , Reativadores da Colinesterase/metabolismo , Acetilcolinesterase/química , Barreira Hematoencefálica/metabolismo , Butirilcolinesterase/química , Inibidores da Colinesterase/química , Reativadores da Colinesterase/química , Humanos , Agentes Neurotóxicos/química , Agentes Neurotóxicos/metabolismo , Oximas/química , Oximas/metabolismo , Praguicidas/química , Praguicidas/metabolismoRESUMO
Novel-substituted phenoxyalkyl pyridinium oxime acetylcholinesterase (AChE) reactivators (US patent 9,227,937) that showed convincing evidence of penetration into the brains of intact rats were developed by our laboratories. The oximes separated into three groups based on their levels of brain AChE reactivation following exposure of rats to the sarin surrogate nitrophenyl isopropyl methylphosphonate (NIMP). P-glycoprotein (P-gp) is a major blood-brain barrier (BBB) transporter and requires ATP for efflux. To determine if P-gp affinity screening could be used to reduce animal use, we measured in vitro oxime-stimulated ATPase activity to see if the in vivo reactivation efficacies related to the oximes' functions as P-gp substrates. High efficacy oximes were expected to be poor P-gp substrates, thus remaining in the brain longer. The high efficacy oximes (24-35% brain AChE reactivation) were worse P-gp substrates than the low efficacy oximes (0-7% brain AChE reactivation). However, the oxime group with medium in vivo reactivation of 10-17% were even worse P-gp substrates than the high efficacy group so their reactivation ability was not reflected by P-gp export. The results suggest that in vitro P-gp ATPase activity can remove the low efficacy oximes from in vivo testing, but is not sufficient to differentiate between the top two tiers.
Assuntos
Membro 1 da Subfamília B de Cassetes de Ligação de ATP/metabolismo , Acetilcolinesterase/metabolismo , Reativadores da Colinesterase/farmacologia , Oximas/farmacologia , Compostos de Piridínio/farmacologia , Alternativas aos Testes com Animais , Animais , Transporte Biológico , Barreira Hematoencefálica/enzimologia , Barreira Hematoencefálica/metabolismo , Membrana Celular/enzimologia , Membrana Celular/metabolismo , Reativadores da Colinesterase/metabolismo , Técnicas In Vitro , Microssomos/enzimologia , Microssomos/metabolismo , Estrutura Molecular , Oximas/metabolismo , Compostos de Piridínio/metabolismo , Ratos , Especificidade por SubstratoRESUMO
Over 50 years ago, the toxicity of irreversible organophosphate inhibitors targeting human acetylcholinesterase (hAChE) was observed to be stereospecific. The therapeutic reversal of hAChE inhibition by reactivators has also been shown to depend on the stereochemistry of the inhibitor. To gain clarity on the mechanism of stereospecific inhibition, the X-ray crystallographic structures of hAChE inhibited by a racemic mixture of VX (P R/S) and its enantiomers were obtained. Beyond identifying hAChE structural features that lend themselves to stereospecific inhibition, structures of the reactivator HI-6 bound to hAChE inhibited by VX enantiomers of varying toxicity, or in its uninhibited state, were obtained. Comparison of hAChE in these pre-reactivation and post-reactivation states along with enzymatic data reveals the potential influence of unproductive reactivator poses on the efficacy of these types of therapeutics. The recognition of structural features related to hAChE's stereospecificity toward VX shed light on the molecular influences of toxicity and their effect on reactivators. In addition to providing a better understanding of the innate issues with current reactivators, an avenue for improvement of reactivators is envisioned.
Assuntos
Acetilcolinesterase/química , Reativadores da Colinesterase/química , Compostos Organotiofosforados/química , Oximas/química , Compostos de Piridínio/química , Acetilcolinesterase/genética , Acetilcolinesterase/metabolismo , Sítios de Ligação , Biocatálise , Domínio Catalítico , Reativadores da Colinesterase/metabolismo , Cristalografia por Raios X , Humanos , Simulação de Dinâmica Molecular , Compostos Organotiofosforados/metabolismo , Oximas/metabolismo , Compostos de Piridínio/metabolismo , Proteínas Recombinantes/biossíntese , Proteínas Recombinantes/química , Proteínas Recombinantes/isolamento & purificação , EstereoisomerismoRESUMO
Six chlorinated bispyridinium mono-oximes, analogous to potent charged reactivators K027, K048, and K203, were synthesized with the aim of improving lipophilicity and reducing the p Ka value of the oxime group, thus resulting in a higher oximate concentration at pH 7.4 compared to nonchlorinated analogues. The nucleophilicity was examined and the p Ka was found to be lower than that of analogous nonchlorinated oximes. All the new compounds efficiently reactivated human AChE inhibited by nerve agents cyclosarin, sarin, and VX. The most potent was the dichlorinated analogue of oxime K027 with significantly improved ability to reactivate the conjugated enzyme due to improved binding affinity and molecular recognition. Its overall reactivation of sarin-, VX-, and cyclosarin-inhibited AChE was, respectively, 3-, 7-, and 8-fold higher than by K027. Its universality, PAMPA permeability, favorable acid dissociation constant coupled with its negligible cytotoxic effect, and successful ex vivo scavenging of nerve agents in whole human blood warrant further analysis of this compound as an antidote for organophosphorus poisoning.
Assuntos
Acetilcolinesterase/metabolismo , Cloro/química , Reativadores da Colinesterase/química , Reativadores da Colinesterase/farmacologia , Agentes Neurotóxicos/farmacologia , Oximas/química , Oximas/farmacologia , Acetilcolinesterase/química , Butirilcolinesterase/metabolismo , Linhagem Celular Tumoral , Fenômenos Químicos , Inibidores da Colinesterase/farmacologia , Reativadores da Colinesterase/síntese química , Reativadores da Colinesterase/metabolismo , Humanos , Isomerismo , Simulação de Acoplamento Molecular , Oximas/síntese química , Oximas/metabolismo , Conformação Proteica , Relação Estrutura-AtividadeRESUMO
Phorate is a highly toxic agricultural pesticide currently in use throughout the world. Like many other organophosphorus (OP) pesticides, the primary mechanism of the acute toxicity of phorate is acetylcholinesterase (AChE) inhibition mediated by its bioactivated oxon metabolite. AChE reactivation is a critical aspect in the treatment of acute OP intoxication. Unfortunately, very little is currently known about the capacity of various oximes to rescue phorate oxon (PHO)-inhibited AChE. To help fill this knowledge gap, we evaluated the kinetics of inhibition, reactivation, and aging of PHO using recombinant AChE derived from three species (rat, guinea pig and human) commonly utilized to study the toxicity of OP compounds and five oximes that are currently fielded (or have been deemed extremely promising) as anti-OP therapies by various nations around the globe: 2-PAM Cl, HI-6 DMS, obidoxime Cl2, MMB4-DMS, and HLö7 DMS. The inhibition rate constants (ki) for PHO were calculated for AChE derived from each species and found to be low (i.e., 4.8×103 to 1.4×104M-1min-1) compared to many other OPs. Obidoxime Cl2 was the most effective reactivator tested. The aging rate of PHO-inhibited AChE was very slow (limited aging was observed out to 48h) for all three species. CONCLUSIONS: (1) Obidoxime Cl2 was the most effective reactivator tested. (2) 2-PAM Cl, showed limited effectiveness in reactivating PHO-inhibited AChE, suggesting that it may have limited usefulness in the clinical management of acute PHO intoxication. (3) The therapeutic window for oxime administration following exposure to phorate (or PHO) is not limited by aging.
Assuntos
Acetilcolinesterase/metabolismo , Inibidores da Colinesterase/metabolismo , Reativadores da Colinesterase/farmacologia , Cloreto de Obidoxima/farmacologia , Oximas/metabolismo , Praguicidas/toxicidade , Forato/toxicidade , Animais , Antídotos/farmacologia , Inibidores da Colinesterase/toxicidade , Reativadores da Colinesterase/metabolismo , Cobaias , Humanos , Cinética , Cloreto de Obidoxima/metabolismo , Oximas/farmacologia , RatosRESUMO
BACKGROUND: Based on in vitro and in vivo rat experiments, the newly developed acetylcholinesterase (AChE) reactivator, K203, appears to be much more effective in the treatment of tabun poisonings than currently fielded oximes. METHODS: To determine if this reactivating efficacy would extend to humans, studies were conducted in vitro using human brain homogenate as the source of AChE. The efficacy of K203 was compared with commercially available oximes; pralidoxime, obidoxime and asoxime (HI-6). RESULTS: Reactivation studies showed that K203 was the most effective reactivator with a second order kinetic constant (kr) of 2142 min- 1. M- 1, which was 51 times higher than that obtained for obidoxime (kr = 42 min- 1. M- 1). Both pralidoxime and asoxime (HI-6) failed to significantly reactivate tabun-inhibited human AChE. DISCUSSION: According to these results and previous studies, using K203, it appears that oxime K203 is the most effective reactivator of tabun-inhibited cholinesterase in several species including humans and should be considered as a possible medical countermeasure to tabun exposure.
Assuntos
Acetilcolinesterase/metabolismo , Antídotos/metabolismo , Inibidores da Colinesterase/metabolismo , Reativadores da Colinesterase/metabolismo , Organofosfatos/metabolismo , Oximas/metabolismo , Compostos de Piridínio/metabolismo , Animais , Encéfalo/enzimologia , Humanos , Simulação de Acoplamento Molecular , RatosRESUMO
Organophosphate (OP) poisoning is a major global health issue; while compounds from this group have been used intensively over the last century, an effective antidote is still lacking. Oxime-type acetylcholinesterase (AChE) reactivators are used to reactivate the OP inhibited AChE. Pralidoxime is the only US Food and Drug Administration approved oxime for therapeutic use but its efficacy has been disappointing. Two novel oximes (K378 and K727) were investigated in silico and in vitro and compared with an experimental oxime (kamiloxime; K-27) and pralidoxime. In silico the molecular interactions between AChE and oximes were examined and binding energies were assessed. LogP (predicted log of the octanol/water partition coefficient) was estimated. In vitro the intrinsic ability of the oximes to inhibit AChE (IC50) and their reactivation potency (R50) when used in paraoxon inhibited human RBC-AChE was determined. Molecular docking revealed that K378 and K727 bind to the peripheral site(s) with high binding energies in contrast to the central binding of K-27 and pralidoxime. LogP values indicating that the novel compounds are significantly less hydrophilic than K-27 or pralidoxime. IC50 of K378 and K727 were comparable (0.9 and 1 µM, respectively) but orders of magnitude lower than comparators. R50 values revealed their inability to reactivate paraoxon inhibited AChE. It is concluded that the novel oximes K378 and K727 are unlikely to be clinically useful. The in silico and in vitro studies described allow avoidance of unnecessary in vivo animal work and contribute to the reduction of laboratory animal use.
Assuntos
Antídotos/farmacologia , Inibidores da Colinesterase/toxicidade , Reativadores da Colinesterase/farmacologia , Simulação de Acoplamento Molecular , Intoxicação por Organofosfatos/tratamento farmacológico , Oximas/farmacologia , Paraoxon/análogos & derivados , Compostos de Pralidoxima/farmacologia , Compostos de Piridínio/farmacologia , Acetilcolinesterase/sangue , Acetilcolinesterase/química , Antídotos/química , Antídotos/metabolismo , Sítios de Ligação , Inibidores da Colinesterase/química , Inibidores da Colinesterase/metabolismo , Reativadores da Colinesterase/química , Reativadores da Colinesterase/metabolismo , Relação Dose-Resposta a Droga , Proteínas Ligadas por GPI/antagonistas & inibidores , Proteínas Ligadas por GPI/sangue , Proteínas Ligadas por GPI/química , Humanos , Masculino , Intoxicação por Organofosfatos/sangue , Intoxicação por Organofosfatos/enzimologia , Oximas/química , Oximas/metabolismo , Paraoxon/química , Paraoxon/metabolismo , Paraoxon/toxicidade , Compostos de Pralidoxima/química , Compostos de Pralidoxima/metabolismo , Ligação Proteica , Conformação Proteica , Compostos de Piridínio/química , Compostos de Piridínio/metabolismo , Relação Estrutura-AtividadeRESUMO
Irreversible inhibition of the acetylcholine esterase upon intoxication with organophosphorus compounds leads to an accumulation of acetylcholine in the synaptic cleft and a subsequent desensitization of nicotinic acetylcholine receptors which may ultimately result in respiratory failure. The bispyridinium compound MB327 has been found to restore functional activity of nAChR thus representing a promising starting point for the development of new drugs for the treatment of organophosphate poisoning. In order to optimize the resensitizing effect of MB327 on nAChR, it would be very helpful to know the MB327 specific binding site to apply structure based molecular modeling. The binding site for MB327 at the nAChR is not known and so far goal of speculations, but it has been shown that MB327 does not bind to the orthosteric acetylcholine binding site. We have used docking calculations to screen the surface of nAChR for possible binding sites of MB327. The results indicate that at least two potential binding sites for MB327 at nAChR are present inside the channel pore. In these binding sites, MB327 intercalates between the γ-α and ß-δ subunits of nAChR, respectively. Both putative MB327 binding sites show an unsymmetrical distribution of surrounding hydrophilic and lipophilic amino acids. This suggests that substitution of MB327-related bispyridinium compounds on one of the two pyridinium rings with polar substituents should have a favorable effect on the pharmacological function.
Assuntos
Reativadores da Colinesterase/metabolismo , Reativadores da Colinesterase/farmacologia , Compostos de Piridínio/metabolismo , Compostos de Piridínio/farmacologia , Receptores Nicotínicos/efeitos dos fármacos , Acetilcolina/química , Animais , Sítios de Ligação/efeitos dos fármacos , Simulação por Computador , Modelos Moleculares , Simulação de Acoplamento Molecular , Estrutura Molecular , Intoxicação por Organofosfatos/tratamento farmacológico , Conformação Proteica , TorpedoRESUMO
Organophosphorus agents (OPs) irreversibly inhibit acetylcholinesterase (AChE) causing a major cholinergic syndrome. The medical counter-measures of OP poisoning have not evolved for the last 30 years with carbamates for pretreatment, pyridinium oximes-based AChE reactivators, antimuscarinic drugs and neuroprotective benzodiazepines for post-exposure treatment. These drugs ensure protection of peripheral nervous system and mitigate acute effects of OP lethal doses. However, they have significant limitations. Pyridostigmine and oximes do not protect/reactivate central AChE. Oximes poorly reactivate AChE inhibited by phosphoramidates. In addition, current neuroprotectants do not protect the central nervous system shortly after the onset of seizures when brain damage becomes irreversible. New therapeutic approaches for pre- and post-exposure treatments involve detoxification of OP molecules before they reach their molecular targets by administrating catalytic bioscavengers, among them phosphotriesterases are the most promising. Novel generation of broad spectrum reactivators are designed for crossing the blood-brain barrier and reactivate central AChE. This is an article for the special issue XVth International Symposium on Cholinergic Mechanisms.
Assuntos
Acetilcolinesterase/metabolismo , Barreira Hematoencefálica/efeitos dos fármacos , Inibidores da Colinesterase/farmacologia , Reativadores da Colinesterase/metabolismo , Fármacos Neuroprotetores/farmacologia , Intoxicação por Organofosfatos/tratamento farmacológico , Animais , Barreira Hematoencefálica/metabolismo , Reativadores da Colinesterase/farmacologia , Humanos , Intoxicação por Organofosfatos/metabolismoRESUMO
Acetylcholinesterase (AChE; EC 3.1.1.7), an essential enzyme of cholinergic neurotransmission in vertebrates, is a primary target in acute nerve agent and organophosphate (OP) pesticide intoxication. Catalytically inactive OP-AChE conjugates formed between the active-center serine and phosphorus of OPs can, in principle, be reactivated by nucleophilic oxime antidotes. Antidote efficacy is limited by the structural diversity of OP-AChE conjugates resulting from differences in the structure of the conjugated OP, the different active-center volumes they occupy when conjugated to the active-center serine of AChE, and the distinct chemical characteristics of both OPs and oximes documented in numerous X-ray structures of OP-conjugated AChEs. Efforts to improve oxime reactivation efficacy by AChE structure-based enhancement of oxime structure have yielded only limited success. We outline here the potential limitations of available AChE X-ray structures that preclude an accurate prediction of oxime structures, which are necessary for association in the OP-AChE gorge and nucleophilic attack of the OP-conjugated phosphorus.
Assuntos
Acetilcolinesterase/química , Antídotos/química , Inibidores da Colinesterase/química , Reativadores da Colinesterase/química , Intoxicação por Organofosfatos/tratamento farmacológico , Oximas/química , Acetilcolinesterase/metabolismo , Animais , Antídotos/metabolismo , Antídotos/uso terapêutico , Inibidores da Colinesterase/metabolismo , Inibidores da Colinesterase/uso terapêutico , Reativadores da Colinesterase/metabolismo , Reativadores da Colinesterase/uso terapêutico , Cristalografia por Raios X , Desenho de Fármacos , Humanos , Intoxicação por Organofosfatos/enzimologia , Oximas/metabolismo , Oximas/uso terapêutico , Estrutura Terciária de Proteína , Relação Estrutura-AtividadeRESUMO
Currently fielded treatments for nerve agent intoxication include atropine, an acetylcholine receptor antagonist, and pralidoxime (2PAM), a small molecule reactivator of acetylcholinesterase (AChE). 2PAM reactivates nerve agent-inhibited AChE via direct nucleophilic attack by the oxime moiety on the phosphorus center of the bound nerve agent. Due to a permanently charged pyridinium motif, 2PAM is not thought to cross the blood brain barrier and therefore cannot act directly in the neuronal junctions of the brain. In this study, ADOC, a non-permanently charged, non-oxime molecule initially identified using pesticide-inhibited AChE, was characterized in vitro against nerve agent-inhibited recombinant human AChE. The inhibitory and reactivation potentials of ADOC were determined with native AChE and AChE inhibited with tabun, sarin, soman, cyclosarin, VX, or VR and then compared to those of 2PAM. Several structural analogs of ADOC were used to probe the reactivation mechanism of the molecule. Finally, guinea pigs were used to examine the protective efficacy of the compound after exposure to sarin. The results of both in vitro and in vivo testing will be useful in the design of future small molecule reactivators.
Assuntos
Acetilcolinesterase/metabolismo , Reativadores da Colinesterase/metabolismo , Agentes Neurotóxicos/metabolismo , Oximas/química , Fenóis/metabolismo , Compostos de Pralidoxima/metabolismo , Acetilcolinesterase/química , Acetilcolinesterase/genética , Animais , Reativadores da Colinesterase/química , Reativadores da Colinesterase/uso terapêutico , Eritrócitos/enzimologia , Cobaias , Meia-Vida , Humanos , Cinética , Masculino , Agentes Neurotóxicos/química , Agentes Neurotóxicos/intoxicação , Intoxicação por Organofosfatos/tratamento farmacológico , Organofosfatos/química , Organofosfatos/metabolismo , Fenóis/química , Fenóis/uso terapêutico , Compostos de Pralidoxima/química , Compostos de Pralidoxima/uso terapêutico , Proteínas Recombinantes/biossíntese , Proteínas Recombinantes/química , Sarina/química , Sarina/metabolismo , Soman/química , Soman/metabolismo , Relação Estrutura-AtividadeRESUMO
The high number of annual fatalities following suicidal poisoning by organophosphorus (OP) pesticides and the recent homicidal use of the chemical warfare nerve agent sarin against civilian population in Syria underlines the continuous threat by these highly toxic agents. The need for an effective treatment of OP poisoning resulted in the implementation of a combination therapy with the muscarinic receptor antagonist atropine and an oxime for the reactivation of OP-inhibited acetylcholinesterase (AChE). Since the invention of the first clinically used oxime pralidoxime (2-PAM) in the 1950s ongoing research attempted to identify more effective oximes. In fact, several thousand oximes were synthesized in the past six decades. These include charged and non-charged compounds, mono- and bispyridinium oximes, asymmetric oximes, oximes with different substitutes and more recently non-oxime reactivators. Multiple in vitro and in vivo studies investigated the potential of oximes to reactivate OP-inhibited AChE and to reverse OP-induced cholinergic signs. Depending on the experimental model, the investigated species and the tested OP largely variable results were obtained by different laboratories. These findings and the inconsistent effectiveness of oximes in the treatment of OP-pesticide poisoned patients led to a continuous discussion on the value of oximes. In order to provide a forward-looking evaluation of the significance of oximes in OP poisoning multiple aspects, including intrinsic toxicity, in vitro reactivation potency, efficacy and pharmacokinetics, as well as the impact of the causative OP have to be considered. The different influencing factors in order to define the benefit and limitations of oximes in OP poisoning will be discussed.